A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients

Phase 1/2 Completed 12 enrolled Cellcolabs Clinical SPV Limited PDC-CRO · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I/IIa study in frail patients is designed to assess the safety of intravenous human allogenic bone marrow-derived mesenchymal stromal cell product StromaForte by reporting the number of adverse events assessed by Common Terminology Criteria. 12 male and female patients aged 60 to 85 years will be enrolled.

Timeline

Start: 2024-01-22
Primary completion: 2025-08-28
Completion: 2025-08-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	StromaForte	Cell therapy	1e+08 cells	Intravenous

Indications

No indication recorded.